Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million
16.03.2023 - - NUZYRA (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business, a 45% Increase Over the Prior Year - Continued Progress on the Rare Disease Nontuberculous Mycobacteria (NTM) & BARDA Project BioShield Anthrax ...
Source: wallstreet-online.de